X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ABBOTT INDIA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ABBOTT INDIA DR. REDDYS LAB/
ABBOTT INDIA
 
P/E (TTM) x 34.3 42.0 81.7% View Chart
P/BV x 3.4 10.5 32.1% View Chart
Dividend Yield % 0.8 0.6 125.6%  

Financials

 DR. REDDYS LAB   ABBOTT INDIA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
ABBOTT INDIA
Mar-16
DR. REDDYS LAB/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3,3976,015 56.5%   
Low Rs2,5603,707 69.1%   
Sales per share (Unadj.) Rs856.51,236.9 69.2%  
Earnings per share (Unadj.) Rs78.0122.2 63.8%  
Cash flow per share (Unadj.) Rs139.9129.0 108.5%  
Dividends per share (Unadj.) Rs20.0035.00 57.1%  
Dividend yield (eoy) %0.70.7 93.3%  
Book value per share (Unadj.) Rs739.8521.2 141.9%  
Shares outstanding (eoy) m165.7421.25 780.0%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.53.9 88.5%   
Avg P/E ratio x38.239.8 96.0%  
P/CF ratio (eoy) x21.337.7 56.5%  
Price / Book Value ratio x4.09.3 43.2%  
Dividend payout %25.728.6 89.6%   
Avg Mkt Cap Rs m493,632103,296 477.9%   
No. of employees `00022.73.0 767.3%   
Total wages/salary Rs m31,0683,370 921.9%   
Avg. sales/employee Rs Th6,259.08,891.8 70.4%   
Avg. wages/employee Rs Th1,369.81,140.0 120.2%   
Avg. net profit/employee Rs Th569.7878.3 64.9%   
INCOME DATA
Net Sales Rs m141,96126,284 540.1%  
Other income Rs m1,715504 340.0%   
Total revenues Rs m143,67626,789 536.3%   
Gross profit Rs m24,7223,665 674.5%  
Depreciation Rs m10,266144 7,109.4%   
Interest Rs m6348 7,827.2%   
Profit before tax Rs m15,5374,017 386.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9651,421 208.7%   
Profit after tax Rs m12,9212,596 497.7%  
Gross profit margin %17.413.9 124.9%  
Effective tax rate %19.135.4 54.0%   
Net profit margin %9.19.9 92.1%  
BALANCE SHEET DATA
Current assets Rs m96,83714,446 670.3%   
Current liabilities Rs m84,1994,725 1,782.1%   
Net working cap to sales %8.937.0 24.1%  
Current ratio x1.23.1 37.6%  
Inventory Days Days7351 142.7%  
Debtors Days Days9820 499.4%  
Net fixed assets Rs m102,5521,113 9,214.8%   
Share capital Rs m829213 390.1%   
"Free" reserves Rs m121,79210,808 1,126.9%   
Net worth Rs m122,62111,076 1,107.0%   
Long term debt Rs m5,4490-   
Total assets Rs m218,16516,241 1,343.3%  
Interest coverage x25.5497.0 5.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.6 40.2%   
Return on assets %6.216.0 38.7%  
Return on equity %10.523.4 45.0%  
Return on capital %12.936.3 35.5%  
Exports to sales %54.60.6 8,881.7%   
Imports to sales %9.412.6 74.0%   
Exports (fob) Rs m77,520162 47,970.3%   
Imports (cif) Rs m13,2743,322 399.5%   
Fx inflow Rs m81,670268 30,473.9%   
Fx outflow Rs m26,3553,927 671.1%   
Net fx Rs m55,315-3,659 -1,511.6%   
CASH FLOW
From Operations Rs m21,4442,514 852.9%  
From Investments Rs m-18,404-800 2,301.9%  
From Financial Activity Rs m-3,692-803 459.8%  
Net Cashflow Rs m-1,144912 -125.5%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.4 7.9 68.4%  
FIIs % 35.3 0.1 35,300.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.1 89.5%  
Shareholders   75,885 18,270 415.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PANACEA BIOTECH  DISHMAN PHARMA  TTK HEALTHCARE  NATCO PHARMA  BIOCON LTD  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jan 19, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS